Letermovir (Prevymis®) in cases of adult CMV-seropositive recipients of an allogenic haemotopoietic stem cell transplant (HSCT)
The National Health Care Institute has carried out an assessment whether letermovir (Prevymis®) is interchangeable with a medicinal product already included in the Medicine Reimbursement System (GVS).
Registration
Letermovir is an orphan drug and is registered for the prophylaxis of cytomegalovirus (CMV)-reactivation and disease in adult CMV-seropositive recipients of an allogenic haematopoietic stem cell transplant (HSCT).
Advice on inclusion in the GVS
No other medicinal products are included in the GVS that are eligible for assessing the interchangeability of letermovir. The National Health Care Institute, advised by the Scientific Advisory Board (WAR), concluded that for the prophylaxis of CMV reactivation and disease in adult CMV-seropositive recipients of an allogenic HSCT, the therapeutic added value of letermovir added to CMV-DNA-control and, if necessary, pre-emptive therapy, is higher than that of CMV-DNA-control alone, and, where necessary, pre-emptive therapy.
The National Health Care Institute advised the Minister to include letermovir (Prevymis®) on List B of the Health Insurance Decree. Inclusion on List 1B will involve additional costs.
This report is a summary of recommendations by the National Health Care Institute. The original text of this excerpt is in Dutch.